ABSTRACT
Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil–lymphocyte ratio <3 was associated both with OS and progression-free survival (50.4 vs 8.4 and 20.0 vs 3.3 months). Conclusion: Sunitinib is active and feasible. Patients receiving <4 full-dose cycles or having increased neutrophil–lymphocyte ratio achieved worse outcomes: therefore, these are present potential predictive factors.
Acknowledgements
Writing assistance was provided by C Drace, English native speaking, of the Scientific Directorate of Istituto Oncologico Veneto, with no use of funds.
Financial & competing interests disclosure
This work was supported in part by the Regione Veneto (Ricerca Finalizzata Regionale 2012). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.